Hearing restoration and the stria vascularis: evidence for the role of the immune system in hearing restoration.
Journal
Current opinion in otolaryngology & head and neck surgery
ISSN: 1531-6998
Titre abrégé: Curr Opin Otolaryngol Head Neck Surg
Pays: United States
ID NLM: 9417024
Informations de publication
Date de publication:
01 Oct 2021
01 Oct 2021
Historique:
entrez:
30
8
2021
pubmed:
31
8
2021
medline:
26
10
2021
Statut:
ppublish
Résumé
This article reviews the current literature regarding the pathogenesis of immune-mediated sensorineural hearing loss, utilizes previously published single-nucleus transcriptional profiles to characterize cytokine and cytokine receptor expression in the adult stria vascularis cell types to support immune system interaction with the stria vascularis and reviews the current literature on immunomodulatory agents currently being used for hearing-restoration treatment. The literature review highlights recent studies that elucidate many cytokines and immune markers, which have been linked to various immune-mediated disease processes that have been observed with sensorineural hearing loss within the stria vascularis and highlights recent publications studying therapeutic targets for these pathways. This review highlights the current literature regarding the pathogenesis of immune-mediated hearing loss. The role of cochlear structures in human temporal bones from patients with immune-mediated sensorineural hearing loss are highlighted, and we review cytokine signalling pathways relevant to immune-mediated sensorineural hearing loss and localize genes encoding both cytokine and cytokine receptors involved in these pathways. Finally, we review immunomodulatory therapeutics in light of these findings and point to opportunities for the application of novel therapeutics by targeting these signalling pathways.
Identifiants
pubmed: 34459799
doi: 10.1097/MOO.0000000000000738
pii: 00020840-202110000-00008
pmc: PMC9047557
mid: NIHMS1800147
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
373-384Subventions
Organisme : Intramural NIH HHS
ID : ZIA DC000088
Pays : United States
Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Vambutas A, Pathak S. AAO: autoimmune and autoinflammatory (disease) in otology: what is new in immune-mediated hearing loss. Laryngoscope Investig Otolaryngol 2016; 1:110–115.
Nakanishi H, Kawashima Y, Kurima K, et al. mutation and cochlear autoinflammation cause syndromic and nonsyndromic hearing loss DFNA34 responsive to anakinra therapy. Proc Natl Acad Sci U S A 2017; 114:E7766–E7775.
Lopez-Escamez JA, Batuecas-Caletrio A, Bisdorff A. Towards personalized medicine in Ménière's disease. F1000Res 2018; 7 (F1000 Faculty Rev):1295.
Gazquez I, Soto-Varela A, Aran I, et al. High prevalence of systemic autoimmune diseases in patients with Menière's disease. PLoS One 2011; 6:e26759.
Rossini BAA, Penido NO, Munhoz MSL, et al. Sudden sensorioneural hearing loss and autoimmune systemic diseases. Int Arch Otorhinolaryngol 2017; 21:213–223.
Frejo L, Martin-Sanz E, Teggi R, et al. Extended phenotype and clinical subgroups in unilateral Meniere disease: a cross-sectional study with cluster analysis. Clin Otolaryngol 2017; 42:1172–1180.
Frejo L, Soto-Varela A, Santos-Perez S, et al. Clinical subgroups in bilateral Meniere disease. Front Neurol 2016; 7:182.
Crossley J, Hussaini AS, Kim HJ, Hoa M. Ménière's disease clinical subtypes in a population from the USA. J Laryngol Otol 2020; 134:24–28.
Lobo D, Tuñón M, Villarreal I, et al. Intratympanic gadolinium magnetic resonance imaging supports the role of endolymphatic hydrops in the pathogenesis of immune-mediated inner-ear disease. J Laryngol Otol 2018; 132:554–559.
Guo P, Sun W, Shi S, et al. Quantitative evaluation of endolymphatic hydrops with MRI through intravenous gadolinium administration and VEMP in unilateral definite Meniere's disease. Eur Arch Otorhinolaryngol 2019; 276:993–1000.
van Steekelenburg JM, van Weijnen A, de Pont LMH, et al. Value of endolymphatic hydrops and perilymph signal intensity in suspected Ménière disease. AJNR Am J Neuroradiol 2020; 41:529–534.
Bier G, Bongers MN, Schabel C, et al. In vivo assessment of an endolymphatic hydrops gradient along the cochlea in patients with Menière's disease by magnetic resonance imaging: a pilot study. Otol Neurotol 2018; 39:e1091–e1099.
Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6:e1000097.
Gu S, Olszewski R, Nelson L, et al. Identification of potential Meniere's disease targets in the adult stria vascularis. Front Neurol 2021; 12:630561.
Gu S, Olszewski R, Taukulis I, et al. Characterization of rare spindle and root cell transcriptional profiles in the stria vascularis of the adult mouse cochlea. Sci Rep 2020; 10:18100.
Orvis J, Gottfried B, Kancherla J, et al. gEAR: Gene expression analysis resource portal for community-driven, multi-omic data exploration. Nat Methods 2021; https://doi.org/10.1038/s41592-021-01200-9
doi: 10.1038/s41592-021-01200-9
Schuknecht HF, Nadol JB. Temporal bone pathology in a case of Cogan's syndrome. Laryngoscope 1994; 104:1135–1142.
Kariya S, Hizli Ö, Kaya S, et al. Histopathologic findings in peripheral vestibular system from patients with systemic lupus erythematosus: a human temporal bone study. Otol Neurotol 2015; 36:1702–1707.
Calzada AP, Balaker AE, Ishiyama G, et al. Temporal bone histopathology and immunoglobulin deposition in Sjogren's syndrome. Otol Neurotol 2012; 33:258–266.
Sone M, Schachern PA, Paparella MM, Morizono N. Study of systemic lupus erythematosus in temporal bones. Ann Otol Rhinol Laryngol 1999; 108:338–344.
Di Stadio A, Ralli M. Systemic lupus erythematosus and hearing disorders: literature review and meta-analysis of clinical and temporal bone findings. J Int Med Res 2017; 45:1470–1480.
Arakelyan A, Nersisyan L, Poghosyan D, et al. Autoimmunity and autoinflammation: a systems view on signaling pathway dysregulation profiles. PLoS One 2017; 12:e0187572.
Strum D, Kim S, Shim T, Monfared A. An update on autoimmune inner ear disease: a systematic review of pharmacotherapy. Am J Otolaryngol 2020; 41:102310.
Pathak S, Vambutas A. Autoimmune inner ear disease patient-associated 28-kDa proinflammatory IL-1β fragment results from caspase-7-mediated cleavage in vitro. JCI Insight 2020; 5:e130845.
Eisner L, Vambutas A, Pathak S. The balance of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 in the autoimmune inner ear disease patients. J Interferon Cytokine Res 2017; 37:354–361.
Peters VA, Joesting JJ, Freund GG. IL-1 receptor 2 (IL-1R2) and its role in immune regulation. Brain Behav Immun 2013; 32:1–8.
Goodall AF, Siddiq MA. Current understanding of the pathogenesis of autoimmune inner ear disease: a review. Clin Otolaryngol 2015; 40:412–419.
Pathak S, Hatam LJ, Bonagura V, Vambutas A. Innate immune recognition of molds and homology to the inner ear protein, cochlin, in patients with autoimmune inner ear disease. J Clin Immunol 2013; 33:1204–1215.
Zhao R, Zhou H, Su SB. A critical role for interleukin-1β in the progression of autoimmune diseases. Int Immunopharmacol 2013; 17:658–669.
Pathak S, Stern C, Vambutas A. N-Acetylcysteine attenuates tumor necrosis factor alpha levels in autoimmune inner ear disease patients. Immunol Res 2015; 63:236–245.
Frejo L, Gallego-Martinez A, Requena T, et al. Proinflammatory cytokines and response to molds in mononuclear cells of patients with Meniere disease. Sci Rep 2018; 8:5974.
Flook M, Frejo L, Gallego-Martinez A, et al. Differential proinflammatory signature in vestibular migraine and Meniere disease. Front Immunol 2019; 10:1229.
Tayer-Shifman OE, Ilan O, Tovi H, Tal Y. Cogan's syndrome -- clinical guidelines and novel therapeutic approaches. Clin Rev Allergy Immunol 2014; 47:65–72.
Shamriz O, Tal Y, Gross M. Autoimmune inner ear disease: immune biomarkers, audiovestibular aspects, and therapeutic modalities of Cogan's syndrome. J Immunol Res 2018; 2018:1498640.
Ahmadi N, Brewer CC, Zalewski C, et al. Cryopyrin-associated periodic syndromes: otolaryngologic and audiologic manifestations. Otolaryngol Head Neck Surg 2011; 145:295–302.
Hui A, Johnson LB, Greemberg R, et al. Severe cryopyrin-associated periodic syndrome first characterized by early childhood-onset sensorineural hearing loss: case report and literature review. Int J Pediatr Otorhinolaryngol 2019; 120:68–72.
Fingerhutová Š, Fráňová J, Hlaváčková E, et al. Muckle-Wells syndrome across four generations in one Czech family: natural course of the disease. Front Immunol 2019; 10:802.
Marchica C, Zawawi F, Basodan D, et al. Resolution of unilateral sensorineural hearing loss in a pediatric patient with a severe phenotype of Muckle-Wells syndrome treated with Anakinra: a case report and review of the literature. J Otolaryngol Head Neck Surg 2018; 47:9.
Nakanishi H, Kawashima Y, Kurima K, et al. NLRP3 mutation and cochlear autoinflammation cause syndromic and nonsyndromic hearing loss DFNA34 responsive to anakinra therapy. Proc Natl Acad Sci U S A 2017; 114:E7766–E7775.
Kuemmerle-Deschner JB, Koitschev A, Tyrrell PN, et al. Early detection of sensorineural hearing loss in Muckle-Wells-syndrome. Pediatr Rheumatol Online J 2015; 13:43.
Goldbach-Mansky R. Current status of understanding the pathogenesis and management of patients with NOMID/CINCA. Curr Rheumatol Rep 2011; 13:123–131.
Mancini P, Atturo F, Di Mario A, et al. Hearing loss in autoimmune disorders: prevalence and therapeutic options. Autoimmun Rev 2018; 17:644–652.
Kiripolsky J, McCabe LG, Kramer JM. Innate immunity in Sjögren's syndrome. Clin Immunol 2017; 182:4–13.
Ziavra N, Politi EN, Kastanioudakis I, et al. Hearing loss in Sjögren's syndrome patients. A comparative study. Clin Exp Rheumatol 2000; 18:725–728.
Ahmadzadeh A, Daraei M, Jalessi M, et al. Hearing status in patients with rheumatoid arthritis. J Laryngol Otol 2017; 131:895–899.
Nasution MES, Haryuna TSH. Elevated matrix metalloproteinase-3 level may affect hearing function in patients with rheumatoid arthritis. J Chin Med Assoc 2019; 82:272–276.
Abad S, Wieërs G, Colau D, et al. Absence of recognition of common melanocytic antigens by T cells isolated from the cerebrospinal fluid of a Vogt-Koyanagi-Harada patient. Mol Vis 2014; 20:956–969.
Couto C, Schlaen A, Frick M, et al. Adalimumab treatment in patients with Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm 2018; 26:485–489.
Stein J, Paulke A, Schacher B, Noehte M. An extraordinary form of the Melkersson-Rosenthal syndrome successfully treated with the tumour necrosis factor-( blocker adalimumab. BMJ Case Rep 2014; 2014:
Um JY, Jang CH, Kim KY, et al. Candidate genes of cerebrovascular disease and sudden sensorineural hearing loss. Clin Appl Thromb Hemost 2010; 16:559–562.
Osnes LT, Nakken B, Bodolay E, Szodoray P. Assessment of intracellular cytokines and regulatory cells in patients with autoimmune diseases and primary immunodeficiencies: novel tool for diagnostics and patient follow-up. Autoimmun Rev 2013; 12:967–971.
Çağdaş D, Sürücü N, Tan Ç, et al. Autoinflammation in addition to combined immunodeficiency: SLC29A3 gene defect. Mol Immunol 2020; 121:28–37.
Jung E, Romero R, Yeo L, et al. The fetal inflammatory response syndrome: the origins of a concept, pathophysiology, diagnosis, and obstetrical implications. Semin Fetal Neonatal Med 2020; 25:101146.
Greco A, De Virgilio A, Ralli M, et al. Behçet's disease: new insights into pathophysiology, clinical features and treatment options. Autoimmun Rev 2018; 17:567–575.
Tsinaslanidou Z, Tsaligopoulos M, Angouridakis N, et al. The expression of TNF-alpha, IL-6, IL-2 and IL-8 in the serum of patients with idiopathic sudden sensorineural hearing loss: possible prognostic factors of response to corticosteroid treatment. Audiol Neurotol 2016; 9–19.
Demirhan E, Eskut NP, Zorlu Y, et al. Blood levels of TNF-α, IL-10, and IL-12 in idiopathic sudden sensorineural hearing loss. Laryngoscope 2013; 123:1778–1781.
Krainer J, Siebenhandl S, Weinhäusel A. Systemic autoinflammatory diseases. J Autoimmun 2020; 109:102421.
Hedrich CM. Shaping the spectrum: from autoinflammation to autoimmunity. Clin Immunol 2016; 165:21–28.
Jo EK, Kim JK, Shin DM, Sasakawa C. Molecular mechanisms regulating NLRP3 inflammasome activation. Cell Mol Immunol 2016; 13:148–159.
Frank D, Vince JE. Pyroptosis versus necroptosis: similarities, differences,;1; and crosstalk. Cell Death Differ 2019; 26:99–114.
Vambutas A, Lesser M, Mullooly V, et al. Early efficacy trial of anakinra in corticosteroid-resistant autoimmune inner ear disease. J Clin Invest 2014; 124:4115–4122.
Vambutas A, DeVoti J, Goldofsky E, et al. Alternate splicing of interleukin-1 receptor type II (IL1R2) in vitro correlates with clinical glucocorticoid responsiveness in patients with AIED. PLoS One 2009; 4:e5293.
Gao Y, Yang J, Cai Y, et al. IFN-(-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling. Int J Cancer 2018; 143:931–943.
Pathak S, Goldofsky E, Vivas EX, et al. IL-1β is overexpressed and aberrantly regulated in corticosteroid nonresponders with autoimmune inner ear disease. J Immunol 2011; 186:1870–1879.
Breslin NK, Varadarajan VV, Sobel ES, Haberman RS. Autoimmune inner ear disease: a systematic review of management. Laryngoscope Investig Otolaryngol 2020; 5:1217–1226.
Ralli M, D’Aguanno V, Di Stadio A, et al. Audiovestibular symptoms in systemic autoimmune diseases. J Immunol Res 2018; 2018:5798103.
Das S, Bakshi SS, Seepana R. Demystifying autoimmune inner ear disease. Eur Arch Otorhinolaryngol 2019; 276:3267–3274.
You YS, Park SW, Yun SK, Lee EJ. Bilateral sudden sensorineural hearing loss with Sweet syndrome: a case report. Medicine (Baltimore) 2020; 99:e22127.
Liu H, Zhou K, Zhang X, Peng KA. Fluctuating sensorineural hearing loss. Audiol Neurootol 2019; 24:109–116.
Penêda JF, Lima NB, Monteiro F, et al. Immune-mediated inner ear disease: diagnostic and therapeutic approaches. Acta Otorrinolaringol Esp 2019; 70:97–104.
Zou J. Autoinflammatory characteristics and short-term effects of delivering high-dose steroids to the surface of the intact endolymphatic sac and incus in refractory Ménière's disease. J Otol 2019; 14:40–50.
Carré F, Blanchard M, Achard S, et al. Pediatric sudden sensorineural hearing loss: experience in a pediatric ENT emergency care center. Int J Pediatr Otorhinolaryngol 2020; 135:110067.
Oz RS, Gluth M, Tesher MS. Pediatric autoimmune inner ear disease: a rare, but treatable condition. Pediatr Ann 2019; 48:e391–e394.
Padoan R, Cazzador D, Pendolino AL, et al. Cogan's syndrome: new therapeutic approaches in the biological era. Expert Opin Biol Ther 2019; 19:781–788.
Tripathi M, Satapathy A, Chauhan RB, et al. Contralateral hearing loss after resection of vestibular Schwannoma in a patient with neurofibromatosis 2: case report and literature review. World Neurosurg 2018; 117:74–79.
Perez-Carpena P, Lopez-Escamez JA. Current understanding and clinical management of Meniere's disease: a systematic review. Semin Neurol 2020; 40:138–150.
D’Aguanno V, Ralli M, de Vincentiis M, Greco A. Optimal management of Cogan's syndrome: a multidisciplinary approach. J Multidiscip Healthc 2018; 11:1–11.
Lu Y, Zhou L, Imrit TS, Liu A. Sudden sensorineural hearing loss in children: clinical characteristics, etiology, treatment outcomes, and prognostic factors. Otol Neurotol 2019; 40:446–453.
Ray A, Prefontaine KE. Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci U S A 1994; 91:752–756.
Lennard CM, Mann EA, Sun LL, et al. Interleukin-1 beta, interleukin-5, interleukin-6, interleukin-8, and tumor necrosis factor-alpha in chronic sinusitis: response to systemic corticosteroids. Am J Rhinol 2000; 14:367–373.
Broughton SS, Meyerhoff WE, Cohen SB. Immune-mediated inner ear disease: 10-year experience. Semin Arthritis Rheum 2004; 34:544–548.
Kim BJ, Kim YH, Lee S, et al. Otological aspects of NLRP3-related autoinflammatory disorder focusing on the responsiveness to anakinra. Rheumatology (Oxford) 2021; 60:1523–1532.
Welzel T, Kuemmerle-Deschner JB. Diagnosis and management of the cryopyrin-associated periodic syndromes (CAPS): what do we know today? J Clin Med 2021; 10:
Iida Y, Wakiguchi H, Okazaki F, et al. Early canakinumab therapy for the sensorineural deafness in a family with Muckle-Wells syndrome due to a novel mutation of NLRP3 gene. Clin Rheumatol 2019; 38:943–948.
Williams R, Hawkins P, Lane T. Recognising and understanding cryopyrin-associated periodic syndrome in adults. Br J Nurs 2019; 28:1180–1186.
Kareva L, Stavrik K, Mironska K. Cryopyrin-associated periodic syndromes and treatment options. Open Access Macedonian J Med Sci 2020; 8:241–245.
Yan R, Cao W, Liu X, et al. A Chinese case series of Schnitzler syndrome and complete remission in one tocilizumab-treated patient. Clin Rheumatol 2020; 39:3847–3852.
Espinoza GM, Wheeler J, Temprano KK, Keller AP. Cogan's syndrome: clinical presentations and update on treatment. Curr Allergy Asthma Rep 2020; 20:46.
Sakano H, Harris JP. Emerging options in immune-mediated hearing loss. Laryngoscope Investig Otolaryngol 2019; 4:102–108.
Mata-Castro N, Sanz-López L, Varillas-Delgado D, García-Fernández A. Intratympanic infliximab is a safe and effective rescue therapy for refractory immune-mediated hearing loss. Eur Arch Otorhinolaryngol 2020; 277:393–400.
Utsunomiya A, Watanabe T, Shizuki K, Jodo S. Successful treatment with adalimumab for autoimmune sensorineural hearing loss in a patient with Behçet's disease. Clin Exp Rheumatol 2019; 37 Suppl 121:164–165.
Orlando F, Naddei R, Stellacci E, et al. Etanercept as a successful therapy in autoinflammatory syndrome related to TRNT1 mutations: a case-based review. Clin Rheumatol 2021.
San S, Lin CD, Tsai ST, et al. Immunoglobulin G4-related disease presented as recurrent otitis media and mixed hearing loss treated with cyclophosphamide and rituximab: a case report. Arch Rheumatol 2019; 34:233–237.
Monferrer-Adsuara C, Remolí-Sargues L, Hernández-Bel L, et al. Rituximab in the treatment of Susac's syndrome: report of a case. Eur J Ophthalmol 2020; 1120672120924545[Online ahead of print].
Jamilloux Y, El Jammal T, Vuitton L, et al. JAK inhibitors for the treatment of autoimmune and inflammatory diseases. Autoimmun Rev 2019; 18:102390.